Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using "Liquid Biopsy"

Next Previous
Trial Profile

A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using "Liquid Biopsy"

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 05 Jan 2023 The trial has been completed in Greece, according to European Clinical Trials Database record.
  • 13 Apr 2022 Results (n=48) detecting EGFR mutations in plasma cfDNA and paired CTC-fractions of NSCLC patients before the initiation of osimertinib presented at the 113th Annual Meeting of the American Association for Cancer Research
  • 04 Jun 2019 Results assessing efficacy outcomes without the T790M mutation in ctDNA at baseline published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top